Optimal cut points for quality of life questionnaire-core 30 (QLQ-C30) scales: Utility for clinical trials and updates of prognostic systems in advanced hepatocellular carcinoma

Oncologist

Volumn 20, Issue 1, 2015, Pages 63-71

  Diouf, Momar ^a,b   Bonnetain, Franck ^b   Barbare, Jean Claude ^a,c   Bouch, Olivier ^d,e   Dahan, Laetitia ^e   Paoletti, Xavier ^f   Filleron, Thomas ^g  

^a AMIENS UNIVERSITY HOSPITAL   (France)

^b DIJON UNIVERSITY HOSPITAL   (France)

^c Fédération Française de Cancérologie Digestive French Society for Digestive Oncology   (France)

^d REIMS UNIVERSITY HOSPITAL   (France)

^e TIMONE HOSPITAL   (France)

^f INSTITUT CURIE   (France)

^g INSTITUT CLAUDIUS REGAUD   (France)

Author keywords

Hepatocellular carcinoma; Optimal cutoff point; Prognostic classification; Quality of life

Indexed keywords

ARTICLE; BARCELONA CLINIC LIVER CANCER SCORE; BONNETAIN AND BARBARE PROGNOSTIC INDEX; CANCER OF THE LIVER ITALIAN PROGRAM SCORE; CANCER PROGNOSIS; DEATH; DIARRHEA; DYSPNEA; FATIGUE; GRETCH SCORE; HEALTH; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL ACTIVITY; PRIORITY JOURNAL; QUALITY OF LIFE; QUALITY OF LIFE QUESTIONNAIRE CORE 30 SCORE; ROLE FUNCTIONING SCORE; SCORING SYSTEM; SURVIVAL RATE; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL (TOPIC); FRANCE; LIVER NEOPLASMS; PATHOLOGY; PROGNOSIS; QUESTIONNAIRE;

CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS AS TOPIC; FRANCE; HUMANS; LIVER NEOPLASMS; PROGNOSIS; QUALITY OF LIFE; SURVEYS AND QUESTIONNAIRES;

EID: 84921301100     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0175     Document Type: Article

References (30)

1. Jemal A, Benter MM, DeSantis C et al. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010;19: 1893-1907.
2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-1917.
3. Diouf M, Filleron T, Barbare JC et al. The added value of quality of life (QoL) for prognosis of overall survival in patients with palliative hepatocellular carcinoma. J Hepatol 2013;58: 509-521.
4. Bonnetain F, Paoletti X, Collette S et al. Quality of life as a prognostic factor of overall survival in patients with advanced hepatocellular carcinoma: Results from two French clinical trials. Qual Life Res 2008;17:831-843.
5. Yeo W, Mo FKF, Koh J et al. Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma. Ann Oncol 2006;17: 1083-1089.
6. Quinten C, Coens C, Mauer M et al. Baseline quality of life as a prognostic indicator of survival: A meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol 2009;10: 865-871.
7. Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors in multiple regression: A bad idea. Stat Med 2006;25:127-141.
8. Roychowdhury DF, Hayden A, Liepa AM. Health-related quality-of-life parameters as independent prognostic factors in advanced or metastatic bladder cancer. J Clin Oncol 2003;21: 673-678.
9. Mazumdar M, Glassman JR. Categorizing a prognostic variable: Review of methods, code for easy implementation and applications to decision-making about cancer treatments. Stat Med 2000; 19:113-132.
10. Williams BA Mandrekar JN, Mandrekar SJ et al. Finding optimal cutpoints for continuous covariates with binary and time-to-event outcomes. Technical Report Series #79. Rochester, MN: Mayo Clinic, 2006., Available at http://www.mayo.edu/research/documents/biostat-79pdf/doc-10027230.
11. Altman DG, Lausen B, Sauerbrei W et al. Dangers of using “optimal” cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994;86:829-835.
12. A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients: The Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998;28:751-755.
13. Llovet JM, Br ú C, Bruix J. Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin Liver Dis 1999;19:329-338.
14. Chevret S, Trinchet JC, Mathieu D et al. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d’Etude et de Traitement du Carcinome H épatocellulaire. J Hepatol 1999;31:133-141.
15. Tournoux-Facon C, Paoletti X, Barbare JC et al. Development and validation of a new prognostic score of death for patients with hepatocellular carcinoma in palliative setting. J Hepatol 2011;54: 108-114.
16. European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: Management of hepatocellular carcinoma. J Hepatol 2012;56:908-943.
17. Huitzil-Melendez FD, Capanu M, O’Reilly EM et al. Advanced hepatocellular carcinoma: Which staging systems best predict prognosis? J Clin Oncol 2010;28:2889-2895.
18. Faraggi D, Simon R. A simulation study of cross validation for selecting an optimal cutpoint in univariate survival analysis. Stat Med 1996;15: 2203-2213.
19. Barbare JC, Bouch é O, Bonnetain F et al. Treatment of advanced hepatocellular carcinoma with long-acting octreotide: A phase III multicentre, randomised, double blind placebo-controlled study. Eur J Cancer 2009;45:1788-1797.
20. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30. A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-376.
21. Fayers PM, Aaronson NK, Bjordal K et al. The EORTC QLQ-C30 Scoring Manual. 3rd edBrussels, Belgium: European Organization for Research and Treatment of Cancer, 2001.
22. Vinh-Hung V, Verkooijen HM, Fioretta G et al. Lymph node ratio as an alternative to pN staging in node-positive breast cancer. J Clin Oncol 2009;27: 1062-1068.
23. Holländer N, Sauerbrei W, Schumacher M. Confidence intervals for the effect of a prognostic factor after selection of an ‘optimal’ cutpoint. Stat Med 2004;23:1701-1713.
24. Van Steen K, Curran D, Kramer J et al. Multicollinearity in prognostic factor analyses using the EORTC QLQ-C30: Identification and impact on model selection. Stat Med 2002;21: 3865-3884.
25. Harrell FE Jr., Lee KL, Mark DB. Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-387.
26. Pencina MJ, D’Agostino RB, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011;30:11-21.
27. Pencina MJ, D’Agostino RB, D’Agostino RB . et al. Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond. Stat Med 2008;27: 157-172; discussion 207-212.
28. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
29. Efficace F, Rosti G, Aaronson N et al. Patient-versus physician-reporting of symptoms and health status in chronic myeloid leukemia. Haematologica 2014;99:788-793.
30. Gotay CC, Kawamoto CT, Bottomley A et al. The prognostic significance of patient-reported out-comes in cancer clinical trials. J Clin Oncol 2008; 26:1355-1363.